Abstract
A new simple, accurate, precise and reproducible RP-HPLC method was developed for the simultaneous estimation of Losartan Potassium, Ramipril and Hydrochlorothiazide in bulk as well as in pharmaceutical dosages form using Symmetry C18 column (4.6 x 150mm, 5mm, Make: Hypersil) in isocratic mode. The mobile phase was consisting of Potassium dihydrogen phosphate (KH2PO4) and Acetonitrile in the ratio of 68:32(%v/v). The detection was carried out at 210 nm. The % mean recoveries of Losartan Potassium, Ramipril and Hydrochlorothiazide were found to be 98.0 to 100.8%, 98.9-100.7%and 98.3 to 101.2% respectively. The method was linear over the concentration range for Losartan 50.0 ppm-110.0 ppm, Ramipril 1.255ppm-2.75ppm & Hydrochlorothiazide 12.5ppm-27.5 ppm. The Limit of Detection and Limit of Quantification of the method were calculated basing on standard deviation of the response and the slope (s) of the calibration curve at approximate level. The Limit of Detection for Hydrochlorothiazide, Ramipril and Losartan were found to be 0.01, 0.078 & 0.07μg/mL respectively and Limit of Quantification for Hydrochlorothiazide, Ramipril and Losartan were found to be 0.05, 0.27 and 0.24μg/mL respectively. The validation of method was carried out utilizing ICH-guidelines. The described HPLC method was successfully employed for the analysis of pharmaceutical formulations containing combined dosage form.
